Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

In Brief: SmithKline Beecham's Tagamet HB

This article was originally published in The Tan Sheet

  • The Tan Sheet

Executive Summary

SmithKline Beecham's Tagamet HB: OTC version of cimetidine is "approvable" at FDA as of June 13. The milestone moves Tagamet closer to becoming the second H2 antagonist approved for OTC use. J&J-Merck's Pepcid AC cleared FDA in April and entered the market in early June. Tagamet HB was recommended for approval by an FDA advisory committee in March. Approval is expected imminently...

Table

View full table

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

EU Parliament OKs New Rules On Use Of Patient Data In Research

Danes Advise Pharma Firms To Test Their Anti-Tamper Devices

Joint Clinical Assessments: EU Guidance On Evidence May Be Flexible For ATMPs And Single Arm Trials

Experts Urge Action On Regulatory Science Collaboration In Korea

See All
UsernamePublicRestriction

Register

PS083947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By